Summit Therapeutics Inc (SMMT) Options

Looking good! upside is tremendous! $100.00 Target
always early!
$SMMT

his Company Generates No Revenue and Its Market Cap Is Over
18.B

RELAX$$$$$

$SMMT was a dollar ICCM is .69 kills cancers across many indications including breast and lung cancers no side effects no IV no pills a platform that kills cancer by freezing it multiple studies done independently with 5 year data with 97% success rate 5 years out.
https://www.prnewswire.com/il/news-releases/icecure-medical-reports-positive-topline-results-from-ice3-cryoablation-breast-cancer-study-achievement-of-96-39-recurrence-free-rate-brings-company-one-step-closer-to-providing-women-a-non-surgical-alternative-to-lumpectomy-302092712.html

100 Billion market cap is coming as more data comes in on multi faceted oncology platform. Safer and more effective than standard of care.

$SMMT

The price they got and the fact that insiders took a majority of the shares are both big positives on this financing.

SMMT new 52 week high

Fundraise Led by Insiders & Leading Biopharma Institutional Investors in a Private Placement

$235 Million in Net Proceeds Raised at Yesterday’s Closing Price of $22.70

But THANKS for edifying me as to WHY the (so-called) LEGENDARY NVDA's stock price is a paltry $106 bucks!! But heck, if they do a generous FORWARD-Split, maybe they can drop that price down to just $16 bucks!!! With a total FLOAT of circa 2.5-TRILLION shares!!!

Ok…whatever you say.

It's big, which held it DOWN somewhat --- but I still LIKE this firm.

Big float? It’s only 96 million. NIO had a good run today and their float is 1.2 billion. NVDA has a float of 23.5 billion. You’re crazy if you think this has a large float.

SMMT: Not quite the $50, or so, that I had guessed might happen today. (But I still don't think the IMPACT of their news is over yet; despite the big stock FLOAT of this curious Firm.)

Hit 21.50.

lol. No

SMMT: Every news service, podcast, & Twitter/X-like website on this PLANET is SCREAMING about this SMMT Pharma UNDERDOG taking-out MERCK in the first 15-seconds of the FIRST ROUND of Cancer-Cures-Smack-Down-2024!!!

"So, ya thought ya had a cute Cancer Cure, Dr. MERCK-ster???!!! WRONG, SUCKAH!!!"


///////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////
I'm writing a BOOK about the American Cars of 1918 --- click below for latest updates!!
https://i.giphy.com/media/v1.Y2lkPTc5MGI3NjExOXVyb2N1NXVkejE5em04cDMyYnRvbDV2ejAzeHdsdmZzc2JxajQwZSZlcD12MV9pbnRlcm5hbF9naWZfYnlfaWQmY3Q9Zw/f1NTdkdbG4XzW/giphy.gif
///////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////

SMMT: Nevertheless, very LIKELY hits $40-$50 bucks a share today.

new highs https://ih.advfn.com/stock-market/NASDAQ/summit-therapeutics-SMMT/stock-news/94513885/form-8-k-current-report

SMMT: Watch out for that 95-million FLOAT!! (Nice news, though.)

Bravo…

BINGO- Summit lung cancer drug shows ‘striking’ benefit over Keytruda

https://finance.yahoo.com/news/summit-lung-cancer-drug-shows-113800395.html

SMMT new 52 high

SMMT new 52 high

I sold 1/2 my position around $9 anticipating a drop down to $5.85 which is where I placed limit order which never filled. I put some of the gains into VolitionRX VNRX @ $0.80 and added to that position when it dropped to $0.65. Liquid biopsy is getting attention of VC's in silicon valley. I see a future where early cancer diagnosis is treated with Ivonescimab. VNRX has a vet product on the market by the way. I think the SMMT collaboration with MD Anderson is brilliant and shows what leadership is all about.

I have been Following Duggan since for the last 25 years made my first big win pcyc buying for dollars and waking up to a $261.00 share price a decade ago I also got into $PLSE a few years ago when it went to 1.30-1.40 range still holding a modest position. It looks like the drug that Summit has Ivonescimab works better then Keytruda in some cancer indications. Holding my 10k shares of SMMT at 2.25 wish I bought more and bought some options. I think we could see another buyout possibly by Merck. This company IceCure ICCM is showing incredible data with 5 year follow up on early breast cancer patients and killing 97% of tumors in breast cancer patients and even killing 92% of tumors in later stage breast cancer patients with larger tumors and feedback from patients and doctors is 100% They also have data showing best in class data for Kidney, Bone and Lung Cancer. Their cryoblast is approved in 15 countries and starting to build some revenue. Most striking about the technology it can be done in less than hour in patient setting with local anesthetic with the patient being able to go back home within hours and getting right back to their routine I could see the stock going over $10.00 1300% return.
$SMMT

Watching the trades on Fidelity active trader pro today, Friday 6/21/24, at 16:00:00 one trade shows up. Volume = 5,808,156 at a price of $7.93 for a total of $46,058,677.08. So 2.2 million in the first 6.5 hours and 5.8 million in one second at exactly 4 pm. I called Fidelity ATP support and they confirm that this is accurate data. It also appears on Yahoo Finance and Finviz. 8.1 million shares traded today. Gotta be short covering. I have never seen anything like this before today. Be great if short sellers were gone, eh?

Watching the trades at the close yesterday, Wednesday 6/12/24, and in the final 15 sec, 502,000 shares @ $8.22 = $4,126,440. Short covering or tute buying in? IDK but I'm thinking this is a market order that gets filled without moving the price. Big money is all I know and it caught my interest. Thought it supports the current price.

Thanks for the link axel.

Summit Therapeutics' Jack West on the company's PD-1xVEGF bi-specific vs Keytruda news

https://www.biotechtv.com/post/summit-therapeutics-june-1-2024

$HUGE

I meant NWBO pre opening trades
Wrong board sorry

I see 2 pre opening trades this morning.

1,400 shares at $,4816
5,100 shares at $,50

TRADING HALT

Here's the link to the JAMA publication: https://jamanetwork.com/journals/jama/fullarticle/2819600
I've spent the afternoon reading it a couple times and here's my $0.02 worth.

The P-values on all the stats are very impressive. The efficacy was P<0.001. Responce rate, ORR, had P<.0.006. "Significant longer PFS duration than chemotherapy alone" was P<0.001. All of these are less than the P<0.05 that is the typical value required. If the Summit P3 trials are still recruiting I would expect there would be considerable effort to get enrolled if you are diagnosed with this type of CA.

I have also seen P3 trials ended early due to ethical considerations but whether or not that applies here is way beyond my pay grade as they say. Frankly, I would struggle with continuing to let the group not receiving Ivonescimab progress their treatments knowing what we know now. Safe to assume that the FDA will require a complete study and analysis. I hope it goes to market quickly which will benefit millions.

Lots of news regarding ASCO, an article published in JAMA (which is no small feat since it is THE JOURNAL of....), conference call Monday, 6/3/24, @ 8 am. Refer to Summit website for the folowing press release.

Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
Publication Entitled: Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial
HARMONi-A was Featured in Oral Presentation at ASCO 2024 on May 31, 2024
Conference Call to be Held at 8:00am ET on Monday, June 3, 2024

Why the HUGE gap up? ...Thanks!!!

If I were to hazard a guess..... Recruiting a person with FDA submissions experience since that will be the next hurdle. You know, get it right the first time and avoid timely delays, resubmissions etc.

This looks like a typical recruitment tool to bring a "heavy hitter" on board. Four years to vest so it keeps them around. It is a common retention tool and a nice feature to have in your employment agreement. It can turn out to be worth considerably more than your salary.

SMMT: But what about THIS (later) news today??? ----
https://finance.yahoo.com/news/summit-therapeutics-reports-inducement-grants-220000000.html

Shs Float 82.98M
Short Float 27.19%

Bad day to be short, eh?
Best one day gain in my life (which occurred in one hour).
Thanks Summit!

Nice trade. Maybe $20 in am. If futures go

Buying at 8.30

Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China

Form 8-K Summit Therapeutics Inc. For: May 24
10K WIZARD 8:35 AM ET 5/24/2024
http://archive.fast-edgar.com/20240524/ANZ2C22CZ22SA2Z2222S22ZZHNTTVZPS7262

Filed on: May 24, 2024

"On May 23, 2024, ASCO released abstracts for presentations to take place during the Annual Meeting. Included in these abstracts, was topline data associated with HARMONi-A. Notably, patients receiving ivonescimab plus chemotherapy experienced a median progression free survival (PFS) by independent radiology review committee (IRRC) of 7.06 months (95% CI: 5.85 – 8.74) as compared to 4.80 months (95% CI: 4.21 – 5.55) for those patients receiving chemotherapy alone (hazard ratio: 0.46; 95% CI: 0.34 – 0.62).


Grade ≥3 treatment emergent adverse events (TEAEs) occurred in 61.5% patients receiving ivonescimab plus chemotherapy as compared to 49.1% patients receiving chemotherapy; the most common grade ≥3 TEAEs were chemotherapy related adverse events.


Additional data and context including, but not limited to, response rates, stable disease rates, progression free survival, overall survival, and safety is expected to be made available during ASCO’s Annual Meeting.


The abstract can be found here (Abstract 8508): https://meetings.asco.org/2024-asco-annual-meeting/15779?presentation=232409#232409"

SMMT under $5

At the end of Mach the insiders added a fair amount. Don't especially like the trend but the weekly chart may be forming a cup and handle. https://stockcharts.com/freecharts/gallery.html?smmt

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Zanganeh Mahkam Chief Executive Officer Mar 27 '24 Buy 3.72 54,321 201,874 24,923,800 Mar 27 08:28 PM
Zanganeh Mahkam Chief Executive Officer Mar 27 '24 Buy 3.72 26,000 96,720 520,814 Mar 27 08:28 PM
Dhingra Ankur Chief Financial Officer Mar 26 '24 Buy 3.75 100,000 375,000 354,958 Mar 27 08:27 PM
Zanganeh Mahkam Chief Executive Officer Mar 26 '24 Buy 3.75 30,000 112,500 30,000 Mar 27 08:28 PM

SMMT under $5

Well the $100 million note has been pushed out until April 2025. I had a couple orders filled on the way DOWN. Rarely a good idea. Need to order a neck brace.

Is it safe to assume there will be a capital raise in the next six months or so since $100 million note is due in September 2024? Stock dilution and volatility is my concern. Trying to figure out when to add to my position. Thoughts?

Third Quarter 2023

Financial Highlights

Aggregate cash and cash equivalents, restricted cash, short-term investments, and receivables on September 30, 2023 totaled $200.5 million as compared to $654.7 million on December 31, 2022.
Our cash, cash equivalents, restricted cash, and short-term investments on September 30, 2023 was $198.9 million as compared to $648.6 million on December 31, 2022. Accounts receivable and research and development tax credits receivable on September 30, 2023 were $1.6 million as compared to $6.1 million on December 31, 2022.
Our short-term investments consist of U.S. treasury securities.
Our current notes payable balance at September 30, 2023 was $100.0 million, which is due in September 2024.
Based on our current cash and investments position, current operating plans, and with the $100.0 million notes payable due in September 2024, we have sufficient funds to operate into the second half of 2024.
Net loss for the three and nine months ended September 30, 2023 was $21.3 million and $578.4 million, respectively. Net loss for the three and nine months ended September 30, 2022 was $21.4 million and $59.6 million, respectively.
The net loss for the nine months ended September 30, 2023 includes one-time in-process research and development expenses associated with the in-licensing of ivonescimab from Akeso of $520.9 million.
Operating cash outflow for the nine months ended September 30, 2023 and 2022 was $57.3 million and $46.8 million, respectively.

I've been looking at the leadership....
https://jackwestmd.com/bio-cv/
https://finance.yahoo.com/news/laura-chow-md-cancer-immunotherapy-204100812.html
I'm impressed!

SMMT new 52 week high

earnings come tuesday feb 20 won't be good.... still a yr away from good profits.

At 4:49 on Valentines Day, 2/14/24, once again two large blocks traded in one minute without moving the price:
16:49:35 $4.45 694,532
16:49:35 $4.45 689,034
The total is: $6,156,868
https://www.nasdaq.com/market-activity/stocks/smmt/after-hours-trades